Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium (99mTc) macrosalb
- Development stage
- Unknown
- Lead developer
- Medi-Radiopharma
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals
- Administration
- Intravenous
01
Overview
Medi-MAA is a diagnostic radiopharmaceutical cold kit containing 2.5 mg of macroaggregated human serum albumin (macrosalb). Upon reconstitution and radiolabeling with sodium pertechnetate (99mTc) solution, it forms technetium (99mTc) macrosalb. The diagnostic agent is administered intravenously, where the macroaggregated particles temporarily lodge in the pulmonary capillary bed via physical microembolisation. This allows for scintigraphic imaging of pulmonary perfusion to evaluate conditions such as pulmonary embolism, chronic circulatory failure, emphysema, and venous circulation disorders.
- Brand names
- Medi-MAA
- Other names
- 99mTc-HSA macroaggregated human albumin99mTc-MAAhuman serum albumin macroaggregatehuman serum albumin macroaggregatesmacroaggregated human albuminmacrosalb (99m Tc)technetium (99mTc) albumin macroaggregatestechnetium tc 99m macrosalbtechnetium-99m macroaggregated albumintechnetium99m macroaggregated albumintechnetium 99m macroaggregated albumin
Beyond the preview
Go deeper on technetium (99mTc) macrosalb.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium (99mTc) macrosalb.